Treatment strategies and outcome in older (>65 y) AML patients
| . | BSC . | LDAC . | GO . | Intensive chemotherapy . | HMAs: Azacitidine (7 d) Decitabine (5 d) . |
|---|---|---|---|---|---|
| CR (%) | 0 | 15-20 | 15-20 | 50-55 | 15-20 |
| Median OS (mo) | 2 | 4 | 4-5 | 10 | 7-10 |
| 5-y OS (%) | 0 | 0 | ? | 10 | Not curative, unless consolidated with allo-HCT |
| Effect in adverse karyotypes | No | No | Limited | Moderate |
| . | BSC . | LDAC . | GO . | Intensive chemotherapy . | HMAs: Azacitidine (7 d) Decitabine (5 d) . |
|---|---|---|---|---|---|
| CR (%) | 0 | 15-20 | 15-20 | 50-55 | 15-20 |
| Median OS (mo) | 2 | 4 | 4-5 | 10 | 7-10 |
| 5-y OS (%) | 0 | 0 | ? | 10 | Not curative, unless consolidated with allo-HCT |
| Effect in adverse karyotypes | No | No | Limited | Moderate |
allo-HCT: allogeneic hematopoietic cell transplantation.